Atlas Trials

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Clinical trial NCT05359081 · TERMINATED

Trial details

NCT number
NCT05359081
Sponsor
Sumitomo Pharma Co., Ltd.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2022-05-16
Primary completion
2024-03-21
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.